University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Stephen Tomlanovich, M.D.

Medical director of the Kidney Transplant Service

Dr. Stephen Tomlanovich is a nationally known kidney transplant specialist and medical director of the UCSF Kidney Transplant Service. He has worked to improve patient access to transplants through the development of outreach clinics in communities throughout Northern California. In his research, he addresses the development of new immunosuppressive medications to prevent organ rejection and minimize side effects.

Tomlanovich is involved with regional and national organizations and serves on the board of directors of the California Transplant Donor Network and the Transpacific Renal Network. He earned a medical degree at the University of Michigan and completed an internship at Rush Presbyterian-St. Luke's Hospital, followed by a residency at Henry Ford Hospital in Detroit. In 1985, he completed a nephrology fellowship at Stanford University and joined UCSF Medical Center.

Clinics

Connie Frank Transplant Center at UCSF
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Kidney Fax: (415) 353-8708
Post-Kidney Fax: (415) 353-8381

Hours: 8 a.m. – 5 p.m.

Pancreas Transplant Services
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Transplant Fax: (415) 353-8708
Post-Transplant Fax: (415) 353-4183

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Stephen Tomlanovich

Education

University of Michigan 1980

Residencies

Henry Ford Hospital, Internal Medicine 1983

Fellowships

Stanford University, Nephrology 1985

Selected Research and Publications

  1. Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012 Dec 15; 94(11):1117-23.
  2. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report. Transplant Proc. 2011 Jun; 43(5):2097-101.
  3. Findlay JY, Fix OK, Paugam-Burtz C, Liu L, Sood P, Tomlanovich SJ, Emond J. Critical care of the end-stage liver disease patient awaiting liver transplantation. Liver Transpl. 2011 May; 17(5):496-510.
  4. Odisho AY, Freise CE, Tomlanovich SJ, Vagefi PA. Inguinal herniation of a transplant ureter. Kidney Int. 2010 Jul; 78(1):115.
  5. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. Clin Transplant. 2010 Jan-Feb; 24(1):73-83.
  6. Tavakol MM, Vincenti FG, Assadi H, Frederick MJ, Tomlanovich SJ, Roberts JP, Posselt AM. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol. 2009 Jul; 4(7):1230-8.
  7. Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, Cooper M, Langone AJ, Tomlanovich SJ. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation. 2007 Dec 15; 84(11):1443-51.
  8. Tomlanovich SJ, Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol. 2007 Mar; 2(2):198-9.
  9. Brennan TV, Fuller TF, Vincenti F, Chan S, Chang CK, Bostrom A, Zlatunich JK, Tomlanovich SJ, Feng S. Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care. Am J Transplant. 2006 Oct; 6(10):2429-35.
  10. Salvadori M, Holzer H, Civati G, Sollinger H, Lien B, Tomlanovich S, Bertoni E, Seifu Y, Marrast AC. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol. 2006 Aug; 66(2):112-9.
  11. McTaggart RA, Tomlanovich SJ, Feng S. Impact of sirolimus on early graft function after deceased-donor kidney transplantation. Transplantation. 2005 Apr 27; 79(8):991; author reply 991-2.
  12. Fuller TF, Feng S, Brennan TV, Tomlanovich S, Bostrom A, Freise CE. Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Transplantation. 2004 Oct 15; 78(7):1030-5.
  13. McTaggart RA, Tomlanovich S, Bostrom A, Roberts JP, Feng S. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation. 2004 Aug 15; 78(3):475-80.
  14. Brennan TV, Freise CE, Fuller TF, Bostrom A, Tomlanovich SJ, Feng S. Early graft function after living donor kidney transplantation predicts rejection but not outcomes. Am J Transplant. 2004 Jun; 4(6):971-9.
  15. Topp KS, Painter PL, Walcott S, Krasnoff JB, Adey D, Sakkas GK, Taylor J, McCormick K, TeNyenhuis M, Iofina M, Tomlanovich S, Stock P. Alterations in skeletal muscle structure are minimized with steroid withdrawal after renal transplantation. Transplantation. 2003 Aug 27; 76(4):667-73.
  16. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003 Jul 27; 76(2):370-5.
  17. Painter P, Taylor J, Wolcott S, Krasnoff J, Adey D, Tomlanovich S, Stock P, Topp K. Exercise capacity and muscle structure in kidney recipient and twin donor. Clin Transplant. 2003 Jun; 17(3):225-30.
  18. Painter PL, Topp KS, Krasnoff JB, Adey D, Strasner A, Tomlanovich S, Stock P. Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. Kidney Int. 2003 Jun; 63(6):2309-16.
  19. McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S, Feng S. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant. 2003 Apr; 3(4):416-23.
  20. Roza A, Tomlanovich S, Merion R, Pollak R, Wright F, Rajagopalan P, Pruett T, Scandling J, Ryan J, Awni W, Schweitzer S, Greco R, Lam W, Nabulsi A, Hoffman R. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation. 2002 Oct 15; 74(7):1013-7.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.